LAHORE: Bayer HealthCare Pakistan organized a symposium to raise awareness of stroke in atrial fibrillation (SPAF) and to highlight its newest treatment.
The Healthcare industry has been on a search for a medication having a high safety profile to prevent stroke in patientsof Atrial Fibrillation. “Xarelto” (rivaroxaban), a ground breaking development in this therapeutic area, is now approved and available in Pakistan, offering significant benefits over Vitamin K Antagonists.
Stroke is among the three most common causes of death, alongside cancer and heart disease and is usually caused due to an irregular heartbeat called atrial fibrillation (AF), which increases the risk of stroke by four to five times. Due to the irregular heartbeat blood clots are formed and hence resulting in stroke.
The likelihood of suffering from AF increases with age so that about one in ten 70 year olds has the condition. If a patient has a stroke and if they survive, their life is changed forever in an instant. As it doesn’t only affect the life of the patient but also affects the patient’s family as well. For patients at risk of having a stroke – and indeed for their families, the misfortune of developing AF need not escalate into the misery of a stroke.
The presentations were followed by Q&A session addressed by well renowned doctors of Pakistan. A number of cardiologists and neurologists participated in the symposium. At the end momentos were also presented to the speakers of the symposium.
This event is part of the concerted efforts by Bayer HealthCare Pakistan to raise awareness about atrial fibrilliation (AF) related diseases and to build capacity of leading doctors in this therapeutic area.